A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Akebia Therapeutics, Inc. is down ~75% from its 2020 highs after its oral anemia candidate vadadustat failed to achieve safety non-inferiority versus standard of care in CKD-NDD patients. Log in to see them here or sign up to get started. The company traded as high as $3.18 and last traded at $3.07. Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. Have Watchlists? CAMBRIDGE - Akebia Therapeutics, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper... | November 25, 2020 AKBA exchanged 5511687 shares on hands in most recent trading session and … FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Find the latest press releases from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue? Privacy Notice, and Akebia Therapeutics, Inc. real time quote is equal to 3.390 USD at 2020-11-29, but your current investment may be devalued in the future. Dow sinks 272 points, but books best November since 1928, and best month since ’87, Arizona, Wisconsin certify election win for Biden, New York zeroes in on hospitals as COVID-19 cases climb, K12 paying ransom to cybercriminals following breach, Tesla stock to be added all at once to S&P 500, Powell says Fed actions unlocked $2 trillion to support economy, Zoom Stocks Falls Despite Another Earnings Blowout, Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho, Akebia Therapeutics started at overweight with $12 stock price target at J.P. Morgan, Akebia Therapeutics started at outperform with $18 stock price target at Raymond James, Akebia and Keryx expect deal to close by year-end, Akebia and Keryx say deal will create company with pro forma equity value of about $1.3 bln, Akebia Therapeutics and Keryx Biopharmaceuticals to merge in all-stock deal, Akebia Therapeutics' stock soars 78% to lead Nasdaq gainers after positive trial results, Akebia's shares jump on late-stage clinical trial results for kidney disease drug, Akebia shares jump on expanded anemia drug deal with Otsuka, Akebia Shares Could More Than Double in a Year. Historical and current end-of-day data provided by FACTSET. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Press Release reported on 11/18/20 that Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500(TM) The Stock rose vividly during the last session to $3.19 after opening rate of $3.16 while the lowest price it went was recorded $3.01 before closing at $3.08. The company’s stock price has collected 13.39% of gains in the last five trading sessions. The high price target for AKBA is $18.00 and the low price target for AKBA is … AKBA 3.39 0.09 (2.73%). Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019© Refinitiv. Source: FactSet. Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More, Akebia Falls as Vadadustat Fails to Meet Safety Endpoint, Top Analyst Upgrades and Downgrades: Akebia, Broadcom, DocuSign, Lululemon, NextEra, Overstock.com, Shopify, Wayfair and More, Implied Volatility Surging for Akebia (AKBA) Stock Options, Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates, Encompass Health Continues to Strengthen Presence in Florida. On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. The fund owned 719,317 shares of the biopharmaceutical company’s stock after buying an additional 715,611 shares during the period. Despite being -2.12% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Oct 19 when the AKBA stock price touched $3.96-6 or saw a rise of 6.57%. View which stocks have been most impacted by COVID-19. Their average twelve-month price target is $10.29, predicting that the stock has a possible upside of 203.41%. Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock “a Buy” and gave the company’s common stock a price target of $15. Analysts have given the company’s stock an average 52-week price target of $6.71, forecast between a low of $3 and high of $10. Data may be intentionally delayed pursuant to supplier requirements. View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. For the best MarketWatch.com experience, please update to a modern browser. ET by Tomi Kilgore Akebia's shares jump on late-stage clinical trial results for kidney disease drug Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Akebia Therapeutics presently has a consensus rating of Buy and an average price target of $9.75. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a … Since then, AKBA shares have decreased by 60.7% and is now trading at $2.73. Intraday Data provided by FACTSET and subject to terms of use. How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry, Akebia Shares Climb on Positive Anemia Drug Study Results, Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. Create a list of the investments you want to track. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -1.03% from its latest closing price compared to the recent 1-year high of $13.71. AKBA is not currently paying a regular dividend. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. The stock had previously closed at $2.88. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s stock price shot up 6.6% during mid-day trading on Monday . Akebia Therapeutics, (AKBA) disclosed a change of 5.00% and its listed share value at $2.73 in the recent trade transaction. There are currently no items in this Watchlist. Do Options Traders Know Something About Akebia (AKBA) Stock We Don't? Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. November 18, 2020. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. All rights reserved. AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Trades from $ 1 Akebia Therapeutics, Inc. (AKBA - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on … Intraday data delayed at least 15 minutes or per exchange requirements. View today's stock price, news and analysis for Akebia Therapeutics Inc. (AKBA). 7 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. The share float percentage for the stock currently stands at 81.57%. Visit a quote page and your recently viewed tickers will be displayed here. Akebia Therapeutics, Inc. (NASDAQ:AKBA) trade information. This company belong to USA Country and part of Healthcare sector. The Investor Relations website contains information about Akebia Therapeutics's business for stockholders, potential investors, and financial analysts. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. If you are looking for stocks with good return, Akebia Therapeutics, Inc. stock can be a bad, high-risk 1-year investment option. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference. Several other experts on Wall Street have posted such reports regarding the AKBA shares. Investors in Akebia Therapeutics (NASDAQ:AKBA), Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Acadian Asset Management LLC lifted its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 19,309.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Copyright 2019© FactSet Research Systems Inc. All rights reserved. By using this site you agree to the Subscriber Agreement & Terms of Use, All quotes are in local exchange time. Cookie Notice. Akebia Therapeutics, Inc. Common Stock (AKBA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s Major holders. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Post-Market 0.02 (0.59%) Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Copyright © 2020 MarketWatch, Inc. All rights reserved. A number of […] Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Simply Wall St. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are … If we look at who the major shareholders are, we find that insiders hold 3.18% of Akebia Therapeutics, Inc. shares while 78.98% of the shares are in the hands of institutional holders. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Fundamental company data and analyst estimates provided by FactSet. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. Barron's also provides information on historical stock ratings, … Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Its products include Auryxia and Vadadustat. International stock quotes are delayed as per exchange requirements. Get Our PREMIUM Forecast Now, from ONLY $6.69! Do … Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Get Akebia Therapeutics alerts: Shares of NASDAQ AKBA opened at $2.38 on Thursday. Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? This browser is no longer supported at MarketWatch. Akebia Therapeutics (AKBA) Gets a Buy Rating from Mizuho Securities, Needham Releases a Buy Rating on Akebia Therapeutics (AKBA), Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates, Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release, Seth Klarman Axes Akebia Therapeutics Stake From Portfolio, Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session. Source: Kantar Media. Let’s start up with the current stock price of Akebia Therapeutics Inc. (AKBA), which is $3.15 to be very precise. Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news and financial information from CNBC. AKBA, Akebia Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Akebia Therapeutics. 8,047,847 shares traded hands during trading, an increase of 130% from the average session volume of 3,494,822 shares. Something went wrong while loading Watchlist.